Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6
Autore:
Verrier, F; Nadas, A; Gorny, MK; Zolla-Pazner, S;
Indirizzi:
Vet Affairs Med Ctr, Res Ctr AIDS & HIV Infect, New York, NY 10010 USA VetAffairs Med Ctr New York NY USA 10010 Infect, New York, NY 10010 USA NYU, Sch Med, Dept Pathol, New York, NY 10016 USA NYU New York NY USA 10016 U, Sch Med, Dept Pathol, New York, NY 10016 USA NYU, Sch Med, Inst Environm Med, New York, NY 10016 USA NYU New York NY USA 10016 Med, Inst Environm Med, New York, NY 10016 USA
Titolo Testata:
JOURNAL OF VIROLOGY
fascicolo: 19, volume: 75, anno: 2001,
pagine: 9177 - 9186
SICI:
0022-538X(200110)75:19<9177:AECTIO>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
HUMAN MONOCLONAL-ANTIBODIES; CD4 BINDING-SITE; RESPIRATORY SYNCYTIAL VIRUS; HIV-1/SIV CHIMERIC VIRUS; RECOMBINANT SOLUBLE CD4; MEDIATED CELL-FUSION; PBL-SCID MICE; SYNERGISTIC NEUTRALIZATION; PASSIVE-IMMUNIZATION; ANTIGENIC DETERMINANTS;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
100
Recensione:
Indirizzi per estratti:
Indirizzo: Zolla-Pazner, S Vet Affairs Med Ctr, Res Ctr AIDS & HIV Infect, Room 18124N,423 E 23rd St,New York, NY 10010 USA Vet Affairs Med Ctr Room 18124N,423 E 23rd St New York NY USA 10010
Citazione:
F. Verrier et al., "Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6", J VIROLOGY, 75(19), 2001, pp. 9177-9186

Abstract

Human immunodeficiency virus-type I (HIV-1) infection elicits antibodies (Abs) directed against several regions of the gp120 and gp41 envelope glycoproteins. Many of these Abs are able to neutralize T-cell-line-adapted strains (TCLA) of HIV-1, but only a few effectively neutralize primary HIV-1 isolates. The nature of HIV-1 neutralization has been carefully studied using human monoclonal Abs (MAbs), and the ability of such MAbs to act in synergyto neutralize HIV-1 has also been extensively studied. However, most synergy studies have been conducted using TCLA strains. To determine the nature of Ab interaction in HIV-1 primary isolate neutralization, a panel of 12 anti-HIV-1 human immunoglobulin G (IgG) MAbs, specific for epitopes in gp120 and gp41, were used. Initial tests showed that six of these MAbs, as well as sCD4, used individually, were able to neutralize the dualtropic primary isolate HIV-1(89.6); MAbs giving significant neutralization at 2 to 10 mug/ml included 2F5 (anti-gp41), 50-69 (anti-gp41), IgG1b12 (anti-gp120(CD4bd)),447-52D (anti-gp120(V3)), 2G12 (anti-gp120), and 670-D (anti-gp120(C5)). For studies of reagent interaction, 16 binary combinations of reagents were tested for their ability to neutralize HIV-189.6. Reagent combinations tested included one neutralizing MAb with sCD4, six pairs consisting of two neutralizing MAbs, and nine pairs consisting of one neutralizing MAb with another non-neutralizing MAb. To assess the interaction of the latter type of combination, a new mathematical treatment of reagent interaction was developed since previously used methods could be used only when both reagents neutralize. Synergy was noted between sCD4 and a neutralizing anti-gp120(V3) MAb. Antagonism was noted between two pairs of anti-gp41 MAbs (one neutralizing and one non-neutralizing). All of the other 13 pairs of MAbs tested displayed only additive effects. These studies suggest that Abs rarely act in synergy to neutralize primary isolate HIV-1(89.6); many anti-HIV-1 Abs act additively to mediate this biological function.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 00:57:26